Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients
Authors:
- 1 October 2011
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 128 (4) , e9-e13
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Heparin Antagonism by Polyvalent Display of Cationic Motifs on Virus‐Like ParticlesChemBioChem, 2009
- Protamine inhibits formation of the covalent factor IXa–anti-thrombin complexBlood Coagulation & Fibrinolysis, 2008
- Improving Heparin Safety: A Multidisciplinary Invited ConferenceHospital Pharmacy, 2008
- Unnatural Amino Acid Incorporation into Virus-Like ParticlesBioconjugate Chemistry, 2008
- Plasma Clearance of Bacteriophage Qβ Particles as a Function of Surface ChargeJournal of the American Chemical Society, 2008
- Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivoJournal of Controlled Release, 2007
- Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary BypassAnesthesia & Analgesia, 2002
- Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary BypassAnesthesia & Analgesia, 2002
- Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine modelAAPS PharmSci, 2001
- ProtamineAnesthesia & Analgesia, 1985